Press Releases

April 15, 2021

Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer

Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Iain Kilty, Ph.D., as its Chief Scientific Officer.

Iain will lead the development and execution of the Company's research strategy and advancement of the Company's pipeline of disease-modifying therapeutics in immuno-oncology and immuno-inflammation.

Neil Weir, Chief Executive Officer of Sitryx, said: "We are delighted to welcome Iain to the Sitryx team. His breadth of experience in leading drug discovery programmes from idea through to clinical development, particularly in the fields of inflammation and immunology, will be critical as we continue to build and progress our pipeline of immunometabolism targeted therapeutic programmes."

Iain said: "Sitryx's high quality science has the potential to transform how we treat severe diseases, such as cancer and autoimmune conditions. I am thrilled to join the Sitryx team, to help drive the science forward and build out the Company's immunometabolism pipeline of disease-modifying therapies for patients."

Iain has more than 20 years of global biopharmaceutical industry experience and has led multiple programmes from idea through to clinical development across a range of indications and therapeutic modalities. He joins Sitryx from Quench Bio where, as Chief Scientific Officer, he was responsible for the company's scientific strategy and execution. Prior to joining Quench, Iain served as Vice President Preclinical Sciences in the Inflammation and Immunology Research Unit at Pfizer, where he was responsible for a portfolio of both small and large molecule programmes targeted across rheumatology, dermatology and gastroenterology. Iain had a 22-year tenure at Pfizer, starting as an internal industrial postdoc and taking on roles of increasing responsibility working across the drug discovery paradigm from target identification to leading the early clinical cluster in Rheumatology and Dermatology. Iain is an Entrepreneur in Residence at Atlas Venture and acts as an industry impact assessor for the UK Government's Research Excellence Framework 2021. He graduated with a BA and MA Cantab in Biochemistry from Jesus College, University of Cambridge, UK, before completing his Ph.D. in the Breast Cancer Research Laboratories at the University of Liverpool, UK.

For more information about Sitryx please contact:

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Melissa Gardiner
+44 (0)20 3709 5700
sitryx@consilium-comms.com

About Sitryx

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism; Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020, Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the Company. The Company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK. For more information, please visit www.sitryx.com.

View PDF Press Release

March 24, 2021

Sitryx appoints Pierre Legault as Chairman of its Board of Directors

Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Pierre Legault BAA, MBA, CA, CPA as Chairman of its Board of Directors. Mr. Legault is a renowned industry leader with over 35 years' international experience in leading biopharmaceutical companies.

Neil Weir, Chief Executive Officer of Sitryx, said: "Pierre's vast global experience in guiding companies through various stages of growth is unrivalled and his expertise in developing and implementing company strategies will be invaluable as we position ourselves as leaders in the field of immunometabolism."

Mr. Pierre Legault, Chairman of the Board of Directors at Sitryx, said: "Immunometabolism targeted therapeutics have the potential to become key, complementary approaches to treating severe diseases, including cancer and autoimmune conditions. I look forward to working with Sitryx's experienced board and management team to help the company reach its full potential to develop disease-modifying therapies for patients and create value for investors."

Mr. Legault currently serves as the Chairman of the Board at Amolyt Pharma, Artios Pharma, Bicycle Therapeutics and Poxel Pharma, is a Board Director at Syndax Pharmaceuticals and was recently Lead Director at Urovant Sciences. In the past, he was a Board Director at Armo Biosciences, Clementia, Tobira Therapeutics, NPS Pharmaceuticals, Forest Laboratories, Regado Biosciences, Iroko Pharmaceuticals, Cyclacel Pharmaceuticals, Eckerd Pharmacy, Nephrogenex (served as the Chairman and CEO) and others. From 2010 to 2012, Mr. Legault served as the CEO of Prosidion Ltd. and from 2009 to 2010, he served as the CFO and Treasurer of OSI Pharmaceuticals. Mr. Legault also served as the CEO of Eckerd Pharmacies and as Senior Executive Vice President and CAO of the Rite Aid Corporation. Between 1989 and 2005, he held various roles such as President, CEO and CFO at legacy companies of Sanofi group. Mr. Legault holds an M.B.A. in Marketing from McGill University and a Bachelor's degree from HEC (University of Montreal). He also studied at Harvard Business School and is a CPA.

For more information about Sitryx please contact:

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Melissa Gardiner
+44 (0)20 3709 5700
sitryx@consilium-comms.com

About Sitryx

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism; Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020, Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the company. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK. For more information, please visit www.sitryx.com.

View PDF Press Release

March 8, 2021

Immunometabolism company Sitryx expands into new space at TOSP
Second occupier for Bellhouse Building at The Oxford Science Park Oxford, UK

Sitryx, a company which is focused on regulating cell metabolism to develop disease-modifying therapeutics in inflammatory diseases and immuno-oncology, announces that it has expanded into new premises in the Bellhouse Building at The Oxford Science Park (TOSP), one of the UK's leading parks for science and technology companies. Sitryx has developed rapidly since its transformative 2020 licensing and research collaboration with pharmaceutical company Eli Lilly. Its new premises provide the ideal environment for growth as its immunometabolism work progresses. Relocating from the Sherrington Building at TOSP, Sitryx is the second occupier of the new Bellhouse Building.

Currently employing 23 staff, of which 16 are research scientists, Sitryx has moved into 5,500 sq ft of purpose-built laboratory and office space. This provides a high-quality lab environment supporting an expanding research team, and a cohesive collaboration environment, supporting all aspects of the company's activities.

In order to inspire science and technology occupiers, and in recognition of his achievements, the Bellhouse building was named after the academic entrepreneur Professor Brian Bellhouse. He read Mathematics at Magdalen College Oxford, which owns TOSP, and become a Professor of Engineering Science. Professor Bellhouse was one of the University's earliest entrepreneurs, forming PowderJect in 1993 and locating it at The Oxford Science Park.

Rory Maw, Bursar of Magdalen College & Director of TOSP, said, 'Fast growing and innovative life sciences companies like Sitryx are core to The Oxford Science Park, and we are delighted to see it expand to the Bellhouse Building. It's always exciting to see companies develop on site and we look forward to supporting Sitryx through its next phase of growth.'

Dr Neil Weir, CEO of Sitryx, said, 'This is an exciting time for us as we scale-up into excellent new premises in the Bellhouse Building, which will house teams working on multiple Lilly and Sitryx projects. We are delighted that this transition into new facilities has gone smoothly, according to timelines, particularly in the current climate.'

About Sitryx

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immunoinflammation. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism; Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak. Together they have published more than 1,000 papers in the field, making multiple key breakthroughs in our understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020 Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly and Company. Lilly also became an investor in the company. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK. For more information, please visit www.sitryx.com.

About The Oxford Science Park

The Oxford Science Park is owned and managed by Magdalen College, Oxford. Created in 1991, the Park upholds the College's heritage and provides one of the most influential science & technology environments in the UK. There is approaching 750,000 square feet of workspace accommodation across the Park, which is now home to 2,700 people and more than 130 businesses. These range from start-ups based in the Magdalen Centre innovation hub to major international companies and include Blue Earth Diagnostics, MiroBio, OrganOx, OxSonics Therapeutics, Oxford Nanopore Technologies, OXGENE, ProImmune, Oxford Sciences Innovation, Evox Therapeutics, Vaccitech, Exscientia, Sensyne Health and Intuitive Surgical.

In addition to being a key property investment, the Park is at the heart of Magdalen College's strategy to support discovery, innovation and entrepreneurship. It will continue to develop The Oxford Science Park as a longterm strategic asset, with ambitious plans to create an additional 500,000+ sq ft of office and laboratory space on the remaining 12 acres of land over the next 3-5 years. This additional capacity will support the growth of businesses already based on the Park, providing flexible workspace accommodation, and enabling new companies to enjoy the Park's exceptional environment and collegiate and collaborative ethos. The Oxford Science Park is located approximately four miles south-east of Oxford city centre, just off the City's southern ring road. It has easy access to the M40 and A34, as well as to Heathrow Airport and mainline train services. For further information, please visit: www.oxfordsp.com or follow us on twitter @OxfordSciencePK

View PDF Press Release